Blue Jet Healthcare Limited (IN:BLUEJET)
:BLUEJET
Want to see IN:BLUEJET full AI Analyst Report?
Top Page
Blue Jet Healthcare Limited
(BLUEJET)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹484.00
▼(-25.93% Downside)
Action:ReiteratedDate:04/28/26
Overall score reflects strong financial performance (rapid revenue growth, high margins, low leverage) tempered by cash flow weakness (negative free cash flow) and a demanding valuation (high P/E with low dividend yield). Technicals add mild support with improving but not strongly bullish longer-term trend signals.
Positive Factors
Revenue Growth
A sustained 45% revenue jump to ₹10,299m demonstrates durable commercial traction in APIs and custom synthesis. Strong top-line growth reflects expanding customer engagements and market penetration in regulated/semi-regulated markets, supporting scalable capacity utilization and long-term revenue visibility.
Negative Factors
Weak Cash Conversion
Operating cash covers only a small portion of reported earnings and FCF turned negative year-over-year, suggesting working-capital pressure or elevated capex. This undermines self-funding for growth, constrains capital returns, and poses a material liquidity risk over the next several months without corrective actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A sustained 45% revenue jump to ₹10,299m demonstrates durable commercial traction in APIs and custom synthesis. Strong top-line growth reflects expanding customer engagements and market penetration in regulated/semi-regulated markets, supporting scalable capacity utilization and long-term revenue visibility.
Read all positive factors
Blue Jet Healthcare Limited (BLUEJET) vs. iShares MSCI India ETF (INDA)
Market Cap
₹76.98B
Dividend Yield0.22%
Average Volume (3M)19.19K
Price to Earnings (P/E)57.2
Beta (1Y)1.16
Revenue Growth20.56%
EPS Growth25.05%
CountryIN
Employees447
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.30
Shares Outstanding173,465,420
10 Day Avg. Volume15,409
30 Day Avg. Volume19,187
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)12.87
Price to Sales (P/S)14.16
P/FCF Ratio-427.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)18.33
Revenue Forecast (FY)₹11.97B
Blue Jet Healthcare Limited Business Overview & Revenue Model
Company Description
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for applications in pharmaceutical and healthcare products. It provides integrated contrast media interm...
How the Company Makes Money
Blue Jet Healthcare Limited makes money mainly by manufacturing and selling pharmaceutical APIs and intermediates to customers in the pharmaceutical value chain. Revenue is generated through (i) product sales of APIs and intermediates, typically s...
Blue Jet Healthcare Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
82
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.79B | 10.30B | 7.10B | 7.18B | 6.77B | 4.94B |
| Gross Profit | 6.16B | 5.69B | 3.89B | 2.70B | 2.97B | 2.47B |
| EBITDA | 4.85B | 4.24B | 2.48B | 2.43B | 2.69B | 2.15B |
| Net Income | 3.52B | 3.05B | 1.64B | 1.60B | 1.82B | 1.38B |
Balance Sheet | ||||||
| Total Assets | 15.27B | 14.18B | 10.59B | 8.62B | 7.13B | 5.36B |
| Cash, Cash Equivalents and Short-Term Investments | 4.11B | 3.06B | 3.09B | 2.55B | 1.81B | 979.70M |
| Total Debt | 206.29M | 199.86M | 16.13M | 68.31M | 228.39M | 516.15M |
| Total Liabilities | 2.72B | 2.84B | 2.14B | 1.81B | 1.92B | 1.96B |
| Stockholders Equity | 12.56B | 11.33B | 8.45B | 6.81B | 5.22B | 3.40B |
Cash Flow | ||||||
| Free Cash Flow | 817.22M | -341.15M | 669.59M | 822.79M | 1.21B | 807.67M |
| Operating Cash Flow | 2.07B | 457.65M | 2.41B | 1.42B | 1.46B | 1.30B |
| Investing Cash Flow | -1.65B | -351.83M | -2.64B | -1.47B | -760.26M | -566.48M |
| Financing Cash Flow | -85.36M | -185.57M | -19.86M | -42.33M | -561.45M | -221.90M |
Blue Jet Healthcare Limited Technical Analysis
Neutral
653.45
Price Trends
383.59
Positive
454.18
Negative
597.53
Negative
Market Momentum
5.14
Negative
62.70
Neutral
89.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Neutral. The current price of 653.45 is above the 20-day moving average (MA) of 366.83, above the 50-day MA of 383.59, and above the 200-day MA of 597.53, indicating a neutral trend. The MACD of 5.14 indicates Negative momentum. The RSI at 62.70 is Neutral, neither overbought nor oversold. The STOCH value of 89.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BLUEJET.
Blue Jet Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹56.74B | 30.45 | ― | 0.13% | 9.68% | 6.17% | |
68 Neutral | ₹76.98B | 57.24 | ― | 0.22% | 20.56% | 25.05% | |
66 Neutral | ₹110.63B | 54.58 | ― | 0.80% | 6.38% | -4.22% | |
63 Neutral | ₹585.87B | 91.56 | ― | 0.12% | 13.99% | -27.80% | |
61 Neutral | ₹117.01B | 59.25 | ― | 0.74% | 1.43% | 29.21% | |
61 Neutral | ₹176.45B | 439.86 | ― | 0.19% | 5.05% | -29.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:BLUEJET
Blue Jet Healthcare Limited
443.15
-242.34
-35.35%
IN:BIOCON
Biocon Limited
362.80
44.43
13.96%
IN:CONCORDBIO
Concord Biotech Ltd.
1,071.05
-477.14
-30.82%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
721.20
71.56
11.01%
IN:SUPRIYA
Supriya Lifescience Limited
704.50
33.67
5.02%
IN:SYNGENE
Syngene International Ltd.
440.00
-186.48
-29.77%
Blue Jet Healthcare Limited Corporate Events
Blue Jet Healthcare Breaks Ground on ₹1,000-Crore Vizag Pharma Facility
Feb 28, 2026
Blue Jet Healthcare has broken ground on a new manufacturing facility at the Industrial Park Rambilli Cluster Phase II in Andhra Pradesh’s Anakapalli district, marking Phase 1 of its Vizag project. The board-approved initial investment of ab...
Blue Jet Healthcare to Build New Manufacturing Facility in Andhra Pradesh
Feb 19, 2026
Blue Jet Healthcare Limited has announced a groundbreaking ceremony for a new manufacturing facility at the Industrial Park Rambilli Cluster Phase II in Anakapalli district, Andhra Pradesh, scheduled for February 28, 2026. The project forms part o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.